文献库搜索 | GeneLibs

Zong(Z),Zhou(X),Shen(J),Yan(M),Xia(X),Li(J... Cancers (Basel) 2026-01-19

...PIK3CA mRNA levels predicted inferior survival in external cohorts. p110α protein expression is an independent biomarker...

Leyva(A),Khan Niazi(MK) Genes (Basel) 2026-01-02

...PIK3CA in oncogenesis, where TP53 is inhibited through disruptive loss-of-function mutations, whereas PIK3CA is recurren...

Ochman(B),Limanówka(P),Mielcarska(S),Kula(... Int J Mol Sci 2026-01-17

...PIK3CA/AKT1 mutations (n = 104). Both TIGIT and CD155 were significantly elevated in tumor tissue versus margins (p < 0....

Pirola(M),Molinaro(E),Manfredini(S),Cuoghi... Int J Mol Sci 2026-01-22

...PIK3CA mutations were observed. Patients experiencing relapse more than six months after diagnosis were more likely to h...

Toromani(G),Saglimbeni(GS),Upadhyayula(BS)... Medicina (Kaunas) 2026-01-07

...PIK3CA (25.5%), TP53 (21.6%), ARID1A (20.6%), and KRAS (16.7%). Significant amplification of ERBB2 was also observed (n ...

Chen(H),Huang(Z),Chang(R),Gao(W),Qiu(Y),Su... Adv Sci (Weinh) 2026-04-00

PIK3CA mutations drive benign adipose overgrowth in facial infiltrating lipomatosis (FIL), but the downstream molecular ...

Greenspun(BC),Metzger(DA),Lee(S),Pearson(B... J Clin Endocrinol Metab 2026-01-21

...PIK3CA, MUC4, PNPLA2, PLD4, EGLN2, BSN, FLNC, RADIL, ZMYND8, FRAS1, RECQL4. More aggressive (n = 37) and less aggressive...

Burge(RA),Bialousow(L),Linke(AJ),Coalson(H... Cancer Res 2026-04-15

...PIK3CA, suggesting that alternative mechanisms might be employed to activate KRASG12R-independent PI3K signaling in PDAC...

Juric(D),Song(K),Johnson(RM),Accordino(MK)... Clin Cancer Res 2026-01-06

PIK3CA mutations frequently drive solid tumors, particularly hormone receptor-positive breast cancer. Inavolisib, an ATP...

Lloyd(MR),Weipert(CM),Ali(A),Solomon(SR),S... Clin Cancer Res 2026-01-06

...PIK3CA, AKT1, and PTEN) had a median TTNT of 5.2 months. In ESR1-mutant MBC, elacestrant treatment durations support the...